Skip to content

ANI Pharmaceuticals ANIP Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.88B+18.3%
Enterprise value$1.87B+5.8%
P/E20.4×
P/S-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's capital investments accrued but not yet paid?
ANI Pharmaceuticals (ANIP) reported capital investments accrued but not yet paid of $784K in Q1 2026.
How has ANI Pharmaceuticals's capital investments accrued but not yet paid changed year-over-year?
ANI Pharmaceuticals's capital investments accrued but not yet paid decreased by 23.3% year-over-year, from $1.02M to $784K.